澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

CLARITY PHARMACEUTICALS LTD

2.480

+0.0903.77%

成交量：113.07萬

成交額：274.28萬

市值：9.23億

市盈率：-8.79

高：2.485

開：2.420

低：2.330

收：2.390

52周最高：5.870

52周最低：1.800

股本：3.72億

流通股本：2.74億

量比：0.53

換手率：0.41%

股息：- -

股息率：- -

每股收益(TTM):-0.282

每股收益(LYR):-0.201

淨資產收益率：-53.45%

總資產收益率：-30.54%

市淨率：3.96

市盈率(LYR):-12.31

資料載入中...

總覽公司新聞資訊公告

Clarity Pharmaceuticals：8 Gbq劑量下81%疾病控制率，31%完全緩解/疾病不可檢測

Clarity Pharmaceuticals與Nucleus Radiopharma簽署Cu-64 SAR-Bispsma商業化生產協議

Clarity Pharmaceuticals與Theragenics簽署銅-64大規模生產供應協議

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/CU6.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":2.48,"timestamp":1787638320000,"preClose":2.39,"halted":0,"volume":1130747,"delay":0,"changeRate":0.037656903765690315,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.282253,"marketStatus":"未開盤","change":0.09,"latestTime":"08-25 16:12:00 AEST","open":2.42,"high":2.485,"low":2.33,"amount":2742784,"amplitude":0.064854,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.282253,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":2.39,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0.5332221253956367,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CU6.AU","preClose":2.48,"auctionPrice":2.48,"auctionVolume":3869,"auctionTime":1787695202264,"referenceTime":1787653803093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787695202264}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-30.54%","roe":"-53.45%","lyrEps":-0.201427,"volumeRatio":0.5332221253956367,"shares":372030071,"dividePrice":0,"high":2.485,"amplitude":0.064854,"preClose":2.39,"low":2.33,"week52Low":1.8,"pbRate":"3.96","psRate":"87.21","week52High":5.87,"institutionHeld":0,"latestPrice":2.48,"eps":-0.282253,"divideRate":0,"volume":1130747,"delay":0,"ttmEps":-0.282253,"open":2.42,"prevYearClose":3.38,"prevWeekClose":2.48,"prevMonthClose":2.37,"prevQuarterClose":2.14,"fiveDayClose":2.57,"twentyDayClose":2.12,"sixtyDayClose":2.36,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1175170356","title":"Clarity Pharmaceuticals：8 Gbq劑量下81%疾病控制率，31%完全緩解/疾病不可檢測","url":"https://stock-news.laohu8.com/highlight/detail?id=1175170356","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175170356?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 21:06","pubTimestamp":1785935169,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals的研究数据显示，在8 Gbq剂量下，患者疾病控制率高达81%。更令人振奋的是，完全缓解或疾病达到不可检测状态的比例达到了31%。这一结果无疑为该公司在癌症治疗领域的探索注入了强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145830308","title":"Clarity Pharmaceuticals與Nucleus Radiopharma簽署Cu-64 SAR-Bispsma商業化生產協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1145830308","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145830308?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 06:35","pubTimestamp":1776119715,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd近日宣布，已与Nucleus Radiopharma达成一项重要合作，双方正式签署了关于放射性药物Cu-64 SAR-Bispsma的商业化生产协议。该协议的签署标志着Clarity在核医学领域的产业化进程迈出关键一步，为其前列腺癌靶向诊疗产品的规模化供应奠定基础。通过此次合作，Nucleus Radiopharma将依托其符合药品生产质量管理规范的生产设施，为Clarity提供符合临床级标准的Cu-64 SAR-Bispsma放射性药物。Cu-64 SAR-Bispsma作为一种新型靶向放射诊疗药物，可通过PET成像技术精准定位前列腺癌病灶，同时具备治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162626167","title":"Clarity Pharmaceuticals與Theragenics簽署銅-64大規模生產供應協議","url":"https://stock-news.laohu8.com/highlight/detail?id=1162626167","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162626167?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 06:25","pubTimestamp":1774391113,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd（以下简称Clarity）近日宣布，已与Theragenics公司达成一项关于铜-64（Copper-64）的大规模生产供应协议。该协议的签署标志着双方在放射性药物领域的合作迈出了重要一步，为Clarity在癌症诊断和治疗方面的产品开发提供了稳定的原材料保障。\n铜-64作为一种重要的医用放射性同位素，在正电子发射断层扫描（PET）成像中具有广泛应用前景。此次大规模供应协议的达成，不仅有助于提升Clarity核心产品的生产能力，也将进一步巩固其在精准医疗领域的市场地位。双方表示，将通过紧密合作确保铜-64的稳定供应，满足未来市场需求的增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}]}}